Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 42 of 307 for:    IBRUTINIB

Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma (R-CHOEP-brut)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03399513
Recruitment Status : Recruiting
First Posted : January 16, 2018
Last Update Posted : October 11, 2018
Sponsor:
Collaborator:
Janssen-Cilag G.m.b.H
Information provided by (Responsible Party):
University Hospital Muenster

Brief Summary:
This study will investigate if treatment results obtained with R-CHOEP in young high-risk patients with diffuse large B-cell lymphoma can be further improved by the addition of ibrutinib to this regimen.

Condition or disease Intervention/treatment Phase
Diffuse Large B Cell Lymphoma Drug: Ibrutinib Oral Capsule [Imbruvica] Drug: R-CHOEP chemotherapy Phase 2

Detailed Description:

Encouraging results have been achieved in younger high-risk patients with newly diagnosed diffuse large B-cell lymphoma treated with R-CHOEP. However, more than one fourth of patients still relapse or show primary progressive disease. The outcome of such patients is poor, in particular if first-line therapy contained rituximab. In order to avoid such detrimental situations, we seek to further improve progression-free survival and overall survival by combining R-CHOEP with ibrutinib.

Ibrutinib is a first-in-class, orally administered, potent, small-molecule inhibitor of Bruton's tyrosine kinase, a mediator of critical B-cell signaling pathways implicated in the pathogenesis of B-cell cancers.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 75 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Ibrutinib and Standard Immuno-Chemotherapy (R-CHOEP-14) in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma
Actual Study Start Date : May 3, 2018
Estimated Primary Completion Date : February 2022
Estimated Study Completion Date : February 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma
Drug Information available for: Ibrutinib

Arm Intervention/treatment
Experimental: Ibrutinib and R-CHOEP chemotherapy

All patients will receive 8 cycles of R-CHOEP immunochemotherapy every two weeks with the following doses per cycle: rituximab 375 mg/m², cyclophosphamide 750 mg/m², doxorubicin 50 mg/m², vincristine 1.4 mg/m² (dose capped at 2 mg), etoposide 300 mg/m², prednisolone 500 mg.

In addition, ibrutinib capsules will be administered orally once daily at a dose of 560 mg (4 x 140 mg hard capsules) for 112 days.

Drug: Ibrutinib Oral Capsule [Imbruvica]
Imbruvica 140 mg hard capsules (Active substance: Ibrutinib)

Drug: R-CHOEP chemotherapy
Immunochemotherapy




Primary Outcome Measures :
  1. 2-year progression-free survival [ Time Frame: From the day of inclusion into the study until one of the following events occurs, whichever is first: disease progression, relapse, death due to any other cause (assessed up to 4 years). ]
    Length of time that a patient lives without disease progression or relapse.


Secondary Outcome Measures :
  1. Overall survival [ Time Frame: From the day of inclusion into the study to death due to any cause (assessed up to 4 years). ]
    The percentage of patients in this study who are still alive.

  2. Event-free survival [ Time Frame: From the day of inclusion into the study until one of the following events occurs, whichever comes first: disease progression, start of additional, unplanned anti-tumor therapy, relapse, death due to any other cause (assessed up to 4 years). ]
    Length of time that a patient remains free of certain events (disease progression, start of additional, unplanned anti-tumor therapy, relapse, death due to any other cause).

  3. Rate of complete remission [ Time Frame: From the day of inclusion into the study until date of complete remission (assessed up to 6 months). ]
    Rate of complete remission measured as number of complete remissions divided by the number of patients included.

  4. Rate of partial remission [ Time Frame: From the day of inclusion into the study until date of partial remission (assessed up to 6 months). ]
    Rate of partial remission measured as number of partial remissions divided by the number of patients included.

  5. Overall response rate [ Time Frame: From the day of inclusion into the study until date of complete or partial remission (assessed up to 6 months). ]
    Overall response rate measured as number of complete and partial remissions divided by the number of patients included.

  6. Progression rate [ Time Frame: From the day of inclusion into the study until date of progression during therapy or within 2 months after last treatment course (assessed up to 6 months). ]
    Progression rate measured as number of progressions divided by the number of patients included.

  7. Relapse rate [ Time Frame: From the day of inclusion into the study until date of relapse during therapy or within 2 months after last treatment course (assessed up to 6 months). ]
    Relapse rate measured as number of relapses divided by the number of patients included.

  8. Duration of response [ Time Frame: From documentation of tumor response to disease progression or relapse (assessed up to 6 months). ]
    The time between the initial response to therapy and subsequent disease progression or relapse.

  9. Adverse events and serious adverse events [ Time Frame: The documentation of adverse events, including serious adverse events, starts with first study treatment after patient inclusion and ends 100 days after the last application of ibrutinib or any component of R-CHOEP (whichever is applied last). ]
    Frequency of adverse events and serious adverse events

  10. Rate of treatment-related deaths [ Time Frame: From the start of therapy up to 2 months after the end of therapy. ]
    The number of deaths during therapy or up to 2 months after the end of therapy divided by the number of patients who started study treatment.

  11. Therapy cycles (number) [ Time Frame: From the start of therapy until the end of therapy (assessed up to 4 months). ]
    Number of therapy cycles

  12. Therapy cycles (duration) [ Time Frame: From the start of therapy until the end of therapy (assessed up to 4 months). ]
    Duration of therapy cycles

  13. Used drugs [ Time Frame: From the start of therapy until the end of therapy (assessed up to 4 months). ]
    Cumulative doses of R-CHOEP (cyclophosphamide, doxorubicin, vincristine, etoposide, rituximab) and ibrutinib.

  14. Outcome according to lymphoma biology [ Time Frame: From the start of study until the end of study (assessed up to 4 years). ]
    Lymphoma tissue from all patients will be characterized.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Sign (or their legally-acceptable representatives must sign) an informed consent document indicating that they understand the purpose of and procedures required for the study, including biomarkers, and are willing to participate in the study.
  2. Age between 18-60 years
  3. Risk score 2 or 3 according to age-adjusted International Prognostic Index
  4. Histology: Primary diagnosis of diffuse large B-cell lymphoma
  5. Performance status: ECOG (toxicity and response criteria of the eastern cooperative oncology group) 0-3
  6. Stage: all stages according Ann Arbor
  7. Absolute neutrophil count: > 1000 cells/microliter (independent of growth factor support)
  8. Platelet count ≥ 100.000/mm³ or ≥ 50.000/mm³ if bone marrow involvement independent of transfusion support in either situation.
  9. Alanine-aminotransferase and Aspartate-aminotransferase: < 3 x Upper limit of normal value
  10. Total Bilirubin: < 1.5 x Upper limit of normal value
  11. Serum Creatinine: < 2 x Upper limit of normal value or estimated Glomerular filtration rate (Glomerular filtration rate [Cockcroft-Gault]) ≥ 40 ml/min
  12. Women of childbearing potential and men who are sexually active must be practising a highly effective method of birth control during and after the study consistent with local regulations regarding the use of birth control methods for subjects participating in clinical trials. Men must agree to not donate sperm during and after the study. For male subjects, these restrictions apply for 6 months after last dose of study drug. For female subjects, they apply for 12 months after last dose of study drug.
  13. Women of childbearing potential must have negative serum or urine beta-human chorionic gonadotropin pregnancy test at screening. Women who are pregnant or breast-feeding are ineligible for this study.
  14. Willing/ able to adhere to the prohibitions and restrictions specified in this protocol.

Exclusion Criteria:

  1. Vaccinated with live, attenuated vaccines within 4 weeks of inclusion.
  2. Major surgery within 4 weeks of inclusion.
  3. Any prior lymphoma-directed therapy (except pre-phase treatment).
  4. Known central nervous system involvement.
  5. Diagnosed or treated for malignancy other than diffuse large B-cell lymphoma, in particular any other (indolent) lymphoma.
  6. Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening, or any class 3 or 4 cardiac disease as defined by the New York Heart Association Functional classification.
  7. Bone marrow involvement > 25%
  8. History of stroke or intracranial hemorrhage within six months of inclusion.
  9. Requires anticoagulation with warfarin or equivalent vitamin K antagonist.
  10. Known history of human immunodeficiency virus or active hepatitis C virus or active hepatitis B virus infection or any uncontrolled active systemic infection requiring IV antibiotics.
  11. Requires treatment with strong CYP3A inhibitors.
  12. Use of preparations containing St. John's Wort.
  13. Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of ibrutinib capsules, or put the study outcomes at undue risk.
  14. Concurrent treatment with other investigational agent or X-ray therapy.
  15. Previous chemo- or radiotherapy for any other malignancy, in particular indolent lymphoma.
  16. Any psychological, cognitive, familial, sociological or geographical condition that, in the investigator's opinion, compromises the patient's ability to understand the patient information, to give informed consent or to comply with the study protocol.
  17. Participation in another interventional clinical trial during this trial. There may be exceptions at the discretion of the coordinating investigator.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03399513


Contacts
Layout table for location contacts
Contact: Birte Friedrichs, MD +49 - (0)251 / 83 - 45375 Birte.Friedrichs@ukmuenster.de

Locations
Layout table for location information
Germany
Universitätsklinikum Münster Recruiting
Münster, Nordrhein-Westfalen, Germany, 48149
Sponsors and Collaborators
University Hospital Muenster
Janssen-Cilag G.m.b.H
Investigators
Layout table for investigator information
Principal Investigator: Prof. Norbert Schmitz, MD University of Münster

Layout table for additonal information
Responsible Party: University Hospital Muenster
ClinicalTrials.gov Identifier: NCT03399513     History of Changes
Other Study ID Numbers: UKM17_0017
First Posted: January 16, 2018    Key Record Dates
Last Update Posted: October 11, 2018
Last Verified: December 2017

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by University Hospital Muenster:
Ibrutinib

Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma
Lymphoma, B-Cell
Lymphoma, Large B-Cell, Diffuse
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin